Media headlines about Henry Schein (NASDAQ:HSIC) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Henry Schein earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.5853413656866 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Henry Schein, Inc. (HSIC) (finance.yahoo.com)
- FTC Sues Dental Products Distributors for Alleged Conspiracy Not to Provide Discounts to a Customer Segment (HSIC) (PDCO) (streetinsider.com)
- Johnson Fistel Investigates Henry Schein, Inc. and Patterson Companies, Inc … (prnewswire.com)
- Henry Schein Shareholder Alert – HSIC Allegedly Involved In Dental Discount Conspiracy – Kehoe Law Firm, P.C. Investigating (finance.yahoo.com)
- IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Investigation of Securities Claims Against Henry Schein, Inc. (finance.yahoo.com)
Several analysts recently commented on the company. Leerink Swann reaffirmed a “hold” rating on shares of Henry Schein in a report on Tuesday. Evercore ISI assumed coverage on Henry Schein in a report on Thursday, January 4th. They issued an “outperform” rating and a $81.00 price objective for the company. Zacks Investment Research raised Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $78.00 price objective on shares of Henry Schein in a report on Wednesday, December 27th. Finally, Deutsche Bank assumed coverage on Henry Schein in a report on Friday, December 8th. They issued a “buy” rating and a $79.00 price objective for the company. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $84.23.
In other Henry Schein news, Director Barry J. Alperin sold 5,796 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the completion of the sale, the director now owns 48,172 shares of the company’s stock, valued at $3,408,650.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.19% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Henry Schein (HSIC) Given Media Impact Rating of 0.17” was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.com-unik.info/2018/02/14/henry-schein-hsic-given-media-impact-rating-of-0-17.html.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.